Regeneron Pharmaceuticals, Inc. announced positive Phase 2 trial results for two novel factor XI antibodies, REGN7508Cat and REGN9933A2, showing robust anti-clotting effects in patients undergoing total knee replacement surgery. These antibodies offer distinct profiles, with one providing stronger anticoagulation and the other reducing bleeding risk. Phase 3 trials are underway to evaluate these antibodies across different patient populations. The results showed significant efficacy in preventing venous thromboembolism (VTE) following surgery, with no major bleeding reported. Regeneron will host a virtual investor event on November 10 to discuss their factor XI development program. Upon registration for a conference call, participants will receive a confirmation email with details on how to join, including a unique passcode and registrant ID. Two trials, ROXI-VTE-I and ROXI-VTE-II, evaluated REGN7508Cat and REGN9933A2 for preventing VTE after knee surgery. Regeneron’s Factor XI program aims to tailor anticoagulation therapy with distinct antibodies. Phase 3 trials are ongoing for VTE prevention after knee surgery. Regeneron utilizes VelocImmune technology to develop human antibodies. The company focuses on developing medicines for various diseases. Regeneron accelerates drug development with proprietary technologies and genetic insights. Forward-looking statements are included in this press release. Regeneron is focusing on developing Factor XI Product Candidates for the prevention of blood clotting in patients undergoing total knee replacement surgery. The company also faces risks associated with regulatory approval, commercial success, and safety of their products. They are also managing supply chains, dealing with reimbursement issues, and monitoring changes in drug pricing regulations. Regeneron is committed to providing important information to investors through their media and investor relations website and social media outlets. Contacts for media and investor relations are provided for further inquiries. 1. The stock market reached record highs today, with the S&P 500 closing at an all-time high of 4,358.12. This surge was driven by strong corporate earnings reports and positive economic data.
2. In international news, the United Nations reported that over 400 civilians have been killed in the ongoing conflict in Ethiopia’s Tigray region. The UN called for an immediate ceasefire to prevent further loss of life.
3. COVID-19 cases continue to rise in several states, with Florida reporting over 12,000 new cases in the past 24 hours. Health officials are urging residents to get vaccinated and practice social distancing to curb the spread of the virus.
4. In sports news, tennis star Naomi Osaka announced that she will not be participating in Wimbledon this year. Osaka cited the need for a mental health break and expressed gratitude for the support she has received from fans and fellow athletes.
Read more at 1. “Tesla announces plans to build new Gigafactory in Texas” – CNBC
2. “Apple reports record-breaking revenue in Q4 earnings” – Wall Street Journal
3. “Amazon Prime Day sales surpass $10 billion globally” – Reuters
4. “Facebook faces antitrust lawsuits from FTC and 48 states” – CBS MarketWatch
5. “Netflix hits milestone of 200 million subscribers worldwide” – Barchart: Phase 2 Trials Demonstrating Antithrombotic Effect of Two